ELRIG, in partnership with The Protein Society, has announced the keynote speakers for Protein Sciences in Drug Discovery 2026, taking place at **GSK** Stevenage from November 10–11. The event offers scientists from academia, pharma, biotech, and CROs a chance to explore emerging developments in protein science and their application to modern drug discovery. This year’s program will investigate AI and machine learning in protein science, challenging targets and complexes, antibody and alternative biologic developability, and non-standard binding protein production challenges.
An early career professional poster award recognizes the research of the next generation of scientists. Prof Dame Carol Robinson, Director of the Kavli Institute for Nanoscience Discovery at the University of Oxford, will present ‘Cell Surface Receptors and Transporters; Insights From Native **MS**’. Robinson is recognized for establishing mass spectrometry as a viable technology to study proteins and their complexes, and founded OMass Technologies. Dr Andrew Doré, Head of Structural Biology at Isomorphic Labs, will discuss ‘Engineering the Future of Drug Discovery: Isomorphic Labs’ AI-First Approach’, having previously delivered multiple **GPCR** structures and advancing drug candidates to the clinic. Prof Paula Booth, Daniell Chair of Chemistry at King’s College London, will present ‘Membrane Protein Tool-kit: Co-translational Folding in Native Lipid Environments’, pioneering approaches at the interface of chemistry and biology to probe membrane protein folding. The event aims to facilitate networking and collaboration across disciplines. The Protein Society values opportunities to engage with the global protein science community, exchange ideas, and strengthen relationships. “The Protein Society is excited to continue our partnership with **ELRIG** to bring together scientists from academia and industry around some of the most rapidly advancing areas of protein science.”